At a glance

Established by Integra Holdings in 2014, NP-09 is at advanced preclinical development of an improved formulation of Propofol, based on technology developed by Prof. Nissim Garti from the Hebrew University. Current Propofol products are widely used for intravenous induction and maintenance of anesthesia, but are manufactured from animal and plant derived components with high risks of bacterial and fungal contamination leading to significant supply shortage, as well as significant manufacturer’s loss of revenues. NP09 is a novel bioequivalent Propofol formulation with proven superiority over Diprivan.

Market Potential

In 2015, Propofol products had a global market of over $1.2 Billion, expected to continue growing at a CAGR of over 7% per annum. Neoprol’s product, NP-09, with long duration patent exclusivity and improved pharmaceutical profile while maintaining bioequivalent effects, may have large market potential.

Company Highlights

A novel, fully synthetic proprietary formulation of Propofol with virtually no risk of contamination, developed based on the technology of Prof. Garti, former Head, Casali Institute of Applied Chemistry and a world leader in surface material science. NP-09 has a short time to market, and represents a high ROI asset with substantial market potential.

Key Shareholders

Integra Holdings, Yissum.

Funding

Extensive business development activity is ongoing to secure the resources required for completion of NP-09 development.